Last updated: July 2, 2026 | By Richard Hale
Devil’s Claw is a plant-based compound with more clinical trial support for joint pain than most supplements on pharmacy shelves. Despite the name, it has no particular mystique — it is a root extract from a Southern African plant (Harpagophytum procumbens) that has been used in traditional medicine for centuries and studied in randomized controlled trials since the 1990s. Whether it belongs in your joint care routine depends on what you are trying to treat and how it compares to the compounds you may already be taking.
This guide covers the evidence, dose, known drug interactions, and what makes Devil’s Claw different from glucosamine, MSM, and other common joint supplements.
This content is for educational purposes only and is not medical advice. Consult a physician before starting any supplement, particularly if you have a diagnosed joint condition or take medication.
Table of Contents
- What Is Devil’s Claw and Where Does It Come From?
- What the Research Actually Shows
- How It Works: The Anti-Inflammatory Pathway
- Dose, Form, and What to Look For on a Label
- How Devil’s Claw Compares to Glucosamine and Other Joint Supplements
- Drug Interactions and Who Should Avoid It
- Frequently Asked Questions
What Is Devil’s Claw and Where Does It Come From?
Devil’s Claw (Harpagophytum procumbens) is a flowering plant native to the Kalahari Desert and southern African savanna, where it grows as a trailing vine with hook-shaped fruit — the origin of its common name. The medicinal portion is the secondary tuber (not the main root), which is harvested, dried, and ground into powder for capsule or tablet formulations.
The active compounds in Devil’s Claw are iridoid glycosides, primarily harpagoside. Harpagoside is what most commercial standardized extracts report on the label, and it is the compound researchers typically measure in clinical trials. Extract quality and concentration vary significantly between products, which is why the harpagoside percentage on the supplement facts panel matters more than the total milligram amount listed.
Devil’s Claw has been registered as a traditional herbal medicine in several European countries — including Germany (via Commission E monograph) and the UK — specifically for the supportive treatment of degenerative musculoskeletal disorders. That level of regulatory recognition is rare for a botanical supplement and reflects the breadth of available clinical evidence.
What the Research Actually Shows
The clinical evidence for Devil’s Claw centers on three conditions: osteoarthritis (particularly of the hip and knee), low back pain, and general musculoskeletal pain. The strength of evidence varies by condition.
Osteoarthritis
Multiple randomized controlled trials have evaluated Devil’s Claw for hip and knee osteoarthritis pain. A widely cited trial published in Phytomedicine (Chrubasik et al., 1996) found that a standardized extract reduced pain scores significantly over 60 days versus placebo. A later Cochrane-cited systematic review (Brien et al., 2006) evaluated trials in musculoskeletal conditions and concluded that evidence supports Devil’s Claw as more effective than placebo for osteoarthritis pain, with effect sizes comparable to low-dose NSAIDs in some trial populations.
The key qualifier: these trials typically use extracts standardized to at least 50–60 mg harpagoside per day. Products with lower harpagoside concentrations — or where concentration is not disclosed — may not match the evidence.
Low Back Pain
Low back pain is where Devil’s Claw has some of its strongest evidence. A large randomized trial (Chrubasik et al., 1999, European Journal of Anaesthesiology) compared Devil’s Claw extract to rofecoxib (a COX-2 inhibitor) in patients with acute exacerbation of chronic low back pain. Devil’s Claw reduced pain scores meaningfully, and a follow-up 2003 trial (Chrubasik et al., Rheumatology) found that a higher-dose extract produced a greater proportion of responders (pain-free or major improvement) than a lower-dose version. Both trials used the same standardized extract (Doloteffin) at approximately 60 mg harpagoside/day.
General Musculoskeletal Pain
A large observational study conducted in Germany (Laudahn and Walper, 2001) followed over 6,000 patients taking Devil’s Claw in routine clinical practice and reported significant pain reduction with low adverse event rates. Observational data carries less weight than RCT data, but the scale and consistency of the finding reinforces the mechanistic evidence below.
How It Works: The Anti-Inflammatory Pathway
Devil’s Claw works through a different anti-inflammatory pathway than most common supplements — and a different one than NSAIDs. This distinction is practically important.
NSAIDs (ibuprofen, naproxen) and COX-2 inhibitors block cyclooxygenase enzymes, which reduces prostaglandin synthesis and downstream inflammation. Devil’s Claw’s primary active compound, harpagoside, appears to inhibit 5-lipoxygenase (5-LOX), a different enzyme in the inflammatory cascade. Some research also suggests harpagoside downregulates NF-κB, a transcription factor that regulates the production of numerous pro-inflammatory cytokines including TNF-alpha and interleukins IL-1β and IL-6.
The practical implication: Devil’s Claw addresses inflammation through pathways that NSAIDs do not fully cover. This is why researchers have studied it as an adjunct to (not replacement for) conventional pain management, and why some joint supplement formulas combine it with compounds that have complementary mechanisms — such as Boswellia (also 5-LOX, but additional pathways) or curcumin (NF-κB inhibition with additional antioxidant effects).
It is not a fast-acting pain reliever. Onset in trials is typically measured over weeks — pain reduction at 4 and 8 weeks compared to baseline — not hours. Patients expecting NSAID-speed response will be disappointed.
Dose, Form, and What to Look For on a Label
The clinical evidence is built around standardized extracts, not raw dried root powder. This matters because the harpagoside content of raw plant material varies significantly between growing regions and harvests.
What to look for on a label:
- Harpagoside per daily serving: 50–100 mg is the range used in most published trials. The 60 mg/day dose (used in the Chrubasik low-back pain trials) is the most replicated benchmark.
- Extract ratio or standardization %: A label might say “Devil’s Claw root extract (3% harpagoside): 1,800 mg per day.” Simple math: 1,800 × 0.03 = 54 mg harpagoside — within the evidence range. A label that lists only total extract weight without a standardization percentage cannot be meaningfully evaluated.
- Whole root powder vs. extract: Whole dried root powder may provide anywhere from less than 1% to 3%+ harpagoside, depending on the source. Without standardization, you cannot know what dose you are getting.
| Label format | Daily dose | Harpagoside delivered | Evidence match? |
|---|---|---|---|
| Extract, 3% harpagoside, 2,000 mg/day | 2,000 mg extract | ~60 mg | Yes — matches trial dose range |
| Extract, unstandardized, 500 mg/day | 500 mg | Unknown | Cannot evaluate |
| Whole root powder, 3,000 mg/day | 3,000 mg powder | Probably 15–60 mg (variable) | Uncertain — depends on batch |
| Extract, 50 mg harpagoside listed directly | Varies | 50 mg | Yes — listed dose meets threshold |
How Devil’s Claw Compares to Glucosamine and Other Joint Supplements
Devil’s Claw and glucosamine serve different functions and are not interchangeable. Understanding the distinction helps clarify who benefits from each — and whether combining them makes sense.
Devil’s Claw vs. Glucosamine
Glucosamine sulfate is studied primarily as a cartilage-building compound — its proposed mechanism involves providing raw material for glycosaminoglycan synthesis in cartilage tissue, with secondary anti-inflammatory effects. The evidence is strongest in mild-to-moderate knee osteoarthritis, with some data showing slowed joint space narrowing over 3 years (Reginster et al., 2001, Lancet). Devil’s Claw, by contrast, works primarily through anti-inflammatory pathways — it does not have evidence for structural cartilage support. For pain and stiffness, Devil’s Claw has stronger short-term evidence in back pain specifically. For long-term structural joint support, glucosamine sulfate has more supporting data.
Devil’s Claw vs. Boswellia
Both Boswellia serrata and Devil’s Claw inhibit 5-LOX. The mechanisms overlap but are not identical — Boswellia’s active compounds (boswellic acids) also inhibit cathepsin G, an enzyme involved in cartilage degradation. The two are commonly combined in multi-ingredient joint formulas precisely because their 5-LOX inhibition is complementary without being redundant. Neither replaces the other; they cover similar but not identical ground.
Devil’s Claw vs. MSM
MSM (methylsulfonylmethane) contributes sulfur for connective tissue maintenance and has some anti-inflammatory activity, but its mechanism and effect size in trials is generally weaker than Devil’s Claw for pain outcomes. MSM is more commonly included as a supporting ingredient in multi-compound joint formulas than as a standalone primary intervention.
The practical takeaway: Devil’s Claw is most useful as a pain and inflammation intervention, particularly for low back pain and hip/knee OA symptoms. It is not a structural supplement. A formula that includes Devil’s Claw alongside glucosamine sulfate and Boswellia covers both the anti-inflammatory and (potentially) structural angles, which is why that combination appears in several well-formulated multi-ingredient joint supplements. For a product that combines all three — see our Sanoflex review for a specific evaluation of a Devil’s Claw-containing joint formula.
Drug Interactions and Who Should Avoid It
Devil’s Claw has a meaningful drug interaction profile that distinguishes it from glucosamine and most other joint supplements. This is not a reason to avoid it categorically, but it warrants attention — particularly for adults over 60 who are more likely to be on multiple medications.
Anticoagulants (Warfarin, Heparin)
Case reports and pharmacological research indicate that Devil’s Claw may potentiate the effect of warfarin, increasing bleeding risk. If you are on anticoagulant therapy, this combination requires medical supervision — do not add Devil’s Claw without telling your prescribing physician first.
Antidiabetic Medications
Animal studies suggest Devil’s Claw may lower blood glucose. In people managing blood sugar with medication (metformin, insulin, sulfonylureas), this could increase hypoglycemia risk. Worth discussing with your prescriber, particularly if your medication doses are already finely calibrated.
Acid-Suppressing Medications
Devil’s Claw is traditionally contraindicated in active peptic ulcers because the bitter glycosides stimulate gastric acid secretion. If you are on proton pump inhibitors (PPIs) for ulcers or GERD, the interaction is not dangerous but may partly counteract the PPI’s effect — discuss timing and use with your physician.
Who Should Avoid Devil’s Claw
- People with active gastric or duodenal ulcers
- People on warfarin or other anticoagulants without prescriber oversight
- Pregnant women (potential uterine-stimulating effect, based on animal data)
- People with gallstones (Devil’s Claw stimulates bile production)
For adults without these conditions and not on the above medications, Devil’s Claw has a favorable safety record across the clinical literature — adverse events in trials are generally mild and GI-related (stomach upset, diarrhea), occurring at low frequency and not significantly different from placebo.
Frequently Asked Questions
How long does it take for Devil’s Claw to work?
Most clinical trials measuring pain outcomes evaluate at 4 to 8 weeks. Some participants report improvement within 2–4 weeks, but the compound is not a fast-acting analgesic — it works through gradual anti-inflammatory pathways rather than blocking pain signals the way NSAIDs or acetaminophen do. Expect 4 weeks before making a meaningful assessment of whether it is helping.
Can I take Devil’s Claw with ibuprofen or naproxen?
There is no established direct interaction between Devil’s Claw and standard NSAIDs. However, combining them provides limited additive benefit since NSAIDs already cover COX inhibition more comprehensively than Devil’s Claw does. From a practical standpoint, Devil’s Claw is more often considered as a longer-term alternative to reduce reliance on NSAIDs — not a combination partner. Check with your physician if you are using NSAIDs regularly.
Is Devil’s Claw the same as cat’s claw?
No. Despite similar common names, these are entirely different plants. Cat’s Claw (Uncaria tomentosa) is a South American vine studied primarily for its immune-modulating effects. Devil’s Claw (Harpagophytum procumbens) is a Southern African root studied for musculoskeletal pain. The research on the two compounds is separate, the mechanisms differ, and they are not interchangeable.
What form does Devil’s Claw come in?
Capsules and tablets containing standardized root extract are the most common commercial forms. Some liquid extract tinctures are available but are less practical for achieving consistent daily doses. Standardized powder extract in capsules is the form used in virtually all clinical research — when evaluating a product, confirm the harpagoside percentage or total harpagoside per serving rather than relying on total milligram weight alone.
Does Devil’s Claw help with gout?
Devil’s Claw is not studied for gout, and the mechanism (5-LOX/NF-κB inhibition) does not address the underlying uric acid metabolism issue central to gout. While some anti-inflammatory benefit might occur during a gout flare, it should not be treated as a gout-specific therapy, and its bile-stimulating effects make it worth discussing with a physician in the context of metabolic conditions.
About the author: Richard Hale is an independent health writer focused on mobility, joint health, and active aging research. He is not a licensed medical professional. All content on VitalMove40 is for educational purposes only and is not a substitute for advice from a qualified healthcare provider.
